Laudanum Uniform Controlled Substances Act, which regulated opium tincture (Laudanum) as a Schedule II substance (currently DEA #9630), placing even tighter controls on the drug. By the late 20th century, laudanum's use was almost exclusively confined to treating severe diarrhea. The current prescribing information for laudanum in the US states that opium tincture's sole indication is as an anti-diarrheal, although the drug is occasionally prescribed off-label for treating pain and neonatal withdrawal syndrome. Several historical varieties of laudanum exist, including Paracelsus' laudanum, Sydenham's Laudanum (also known as "tinctura opii crocata"), benzoic laudanum ("tinctura opii benzoica"), and deodorized tincture of opium (the
Laudanum other such drugs continued to be legally available without prescription as long as they were labeled. It is estimated that sale of patent medicines containing opiates decreased by 33% after labeling was mandated. In 1906 in Britain and in 1908 in Canada "laws requiring disclosure of ingredients and limitation of narcotic content were instituted". The Harrison Narcotics Tax Act of 1914 restricted the manufacture and distribution of opiates, including laudanum, and coca derivatives in the US. This was followed by France's "" in 1916, and Britain's Dangerous Drugs Act in 1920. Laudanum was supplied to druggists and physicians in regular